Skip to main content

Zepzelca Side Effects

Generic name: lurbinectedin

Medically reviewed by Drugs.com. Last updated on Sep 13, 2023.

Note: This document contains side effect information about lurbinectedin. Some dosage forms listed on this page may not apply to the brand name Zepzelca.

Applies to lurbinectedin: intravenous powder for solution.

Serious side effects of Zepzelca

Along with its needed effects, lurbinectedin (the active ingredient contained in Zepzelca) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking lurbinectedin:

More common

Less common

Incidence not known

Other side effects of Zepzelca

Some side effects of lurbinectedin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to lurbinectedin: intravenous powder for injection.

General

The most common adverse reactions (20% or more), including laboratory abnormalities, were leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium, and diarrhea.[Ref]

Cardiovascular

Very common (10% or more): Chest pain (up to 10%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 37%), constipation (up to 31%), vomiting (up to 22%), diarrhea (up to 20%), abdominal pain (up to 11%)[Ref]

Abdominal pain included upper abdominal pain and abdominal discomfort[Ref]

Hematologic

Very common (10% or more): Decreased leukocytes (up to 79%), decreased lymphocytes (up to 79%), decreased hemoglobin (up to 74%), decreased neutrophils (up to 71%), decreased platelets (up to 37%)

Frequency not reported: Neutropenia, febrile neutropenia, anemia, thrombocytopenia[Ref]

Hepatic

Very common (10% or more): Increased ALT (up to 66%), increased AST (up to 26%)[Ref]

Local

Postmarketing reports: Extravasation including tissue necrosis requiring debridement[Ref]

Metabolic

Very common (10% or more): Decreased appetite (up to 33%), increased glucose (up to 52%)

Postmarketing reports: Tumor lysis syndrome[Ref]

Musculoskeletal

Musculoskeletal pains included back pain, arthralgia, pain in extremity, musculoskeletal chest pain, neck pain, bone pain, and myalgia.[Ref]

Very common (10% or more): Musculoskeletal pain (up to 33%)

Postmarketing reports: Rhabdomyolysis[Ref]

Nervous system

Peripheral neuropathy included neuralgia, paresthesia, peripheral sensory neuropathy, hypoesthesia, and hyperesthesia.[Ref]

Very common (10% or more): Peripheral neuropathy (up to 11%), headache (up to 10%)

Frequency not reported: Dysgeusia[Ref]

Other

Very common (10% or more): Fatigue (up to 77%), pyrexia (up to 13%), decreased albumin (up to 32%), decreased sodium (up to 31%), decreased magnesium (up to 22%)[Ref]

Renal

Very common (10% or more): Increased creatinine (up to 69%)[Ref]

Respiratory

Very common (10% or more): Dyspnea (up to 31%), cough including productive cough (up to 20%), respiratory tract infection (up to 18%), pneumonia including lung infection (up to 10%)

Frequency not reported: Pneumonitis[Ref]

Respiratory tract infection included upper respiratory tract infection, viral respiratory tract infection, and bronchitis.[Ref]

References

1. Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals. 2020.

2. Product Information. Zepzelca (lurbinectedin). Specialised Therapeutics Pharma Pty Ltd. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.